Cargando…
Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169463/ https://www.ncbi.nlm.nih.gov/pubmed/35717898 http://dx.doi.org/10.1016/j.msard.2022.103938 |
| _version_ | 1784721212402827264 |
|---|---|
| author | Mouliou, Dimitra S. Dardiotis, Efthimios |
| author_facet | Mouliou, Dimitra S. Dardiotis, Efthimios |
| author_sort | Mouliou, Dimitra S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9169463 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91694632022-06-07 Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing? Mouliou, Dimitra S. Dardiotis, Efthimios Mult Scler Relat Disord Correspondence Elsevier B.V. 2022-08 2022-06-06 /pmc/articles/PMC9169463/ /pubmed/35717898 http://dx.doi.org/10.1016/j.msard.2022.103938 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Mouliou, Dimitra S. Dardiotis, Efthimios Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing? |
| title | Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing? |
| title_full | Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing? |
| title_fullStr | Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing? |
| title_full_unstemmed | Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing? |
| title_short | Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing? |
| title_sort | temelimab for ms and sars-cov-2: could it be a double-edged blessing? |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169463/ https://www.ncbi.nlm.nih.gov/pubmed/35717898 http://dx.doi.org/10.1016/j.msard.2022.103938 |
| work_keys_str_mv | AT moulioudimitras temelimabformsandsarscov2coulditbeadoubleedgedblessing AT dardiotisefthimios temelimabformsandsarscov2coulditbeadoubleedgedblessing |